These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22174609)

  • 61. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
    Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
    Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression of 6 common antigenic markers in invasive ductal breast carcinoma: potential clinical implications.
    Lialiaris TS; Kouskoukis A; Georgiou G; Tripsianis G; Fiska A; Giatromanolaki A; Chrisafi S; Sivridis E; Vamvakopoulou DN; Soutopoulou DO; Kiritsaka A; Athanassiou E; Lialios GA; Sotiriou S; Sidiropoulos A; Vamvakopoulos NC
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):106-11. PubMed ID: 20724920
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells.
    Chen M; He M; Song Y; Chen L; Xiao P; Wan X; Dai F; Shen P
    Int J Mol Med; 2014 Jul; 34(1):276-82. PubMed ID: 24804820
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Howell SJ; Wardley AM; Armstrong AC
    J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
    [No Abstract]   [Full Text] [Related]  

  • 67. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 68. BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma.
    Tang SC; Beck J; Murphy S; Chernenko G; Robb D; Watson P; Khalifa M
    Breast Cancer Res Treat; 2004 Apr; 84(3):203-13. PubMed ID: 15026618
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.
    de Cremoux P; Tran-Perennou C; Brockdorff BL; Boudou E; Brünner N; Magdelénat H; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Sep; 10(3):409-18. PubMed ID: 14503918
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.
    Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Ikeda K; Ogawa Y; Ishikawa T; Hirakawa K
    Breast Cancer Res; 2011; 13(6):R122. PubMed ID: 22126395
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.
    Xie Y; Li X; Wu Y; Cui W; Liu Y
    World J Surg Oncol; 2022 Oct; 20(1):338. PubMed ID: 36224558
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
    Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
    Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Immunophenotype of Nodular Variant of Medullary Carcinoma of the Breast.
    Reyes C; Nadji M
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):624-7. PubMed ID: 25710588
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
    Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
    Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
    Erdem O; Dursun A; Coşkun U; Günel N
    Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients.
    Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Kim S; Choe JH; Lee JE; Kim JH; Kim JS; Nam SJ; Yang JH
    Breast Cancer Res Treat; 2011 Apr; 126(2):471-8. PubMed ID: 21287362
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.